Sarcopenia Therapeutics - Pipeline Assessment and Market Forecasts to 2018
NEW YORK, Oct. 27, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Sarcopenia Therapeutics - Pipeline Assessment and Market Forecasts to 2018
http://www.reportlinker.com/p0661236/Sarcopenia-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication
Sarcopenia Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Summary
GlobalData, the industry analysis specialist, has released its new report, "Sarcopenia Therapeutics - Pipeline Assessment and Market Forecasts to 2018". The report is an essential source of information and analysis on the global sarcopenia therapeutics market. The report identifies the key trends shaping and driving the global sarcopenia therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global sarcopenia therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.
Global Data estimates that the global sarcopenia therapeutics market was valued at $10.1m in 2010. The market is forecasted to witness a consistent growth with a Compound Annual Growth Rate (CAGR) of 9.6% in the next eight years and it is expected to reach $20.9m in the year 2018. This is inclusive of the markets of the US, the UK, Italy and Japan. The growth in the market is primarily attributed to increases in aging populations. The limited valuation of the market is due to the fact that drug therapy is not recommended as the first line treatment for sarcopenia. At present, no drug has been approved for treating sarcopenia. The current competitive landscape consists of only generic and off-label drugs such as testosterone, estrogen and growth hormones. In countries such as Germany, Spain and France, no pharmacological treatment is being prescribed for treating sarcopenia so these countries were not included when estimating the global sarcopenia therapeutics market. The treatment landscape is not going to witness any major change in the future due to lack of promising drugs in the late stage pipeline. The global sarcopenia market is expected to remain as a low value market during the forecast period due to the domination of off-label drugs.
Note: This is a on-demand report and will be delivered within 3 business days of the purchase (excluding weekends).
Scope
The report provides information on the key drivers and challenges of the sarcopenia therapeutics market. Its scope includes -
- Annualized global sarcopenia therapeutics market revenues data from 2005 to 2010, forecast for eight years to 2018.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes such as androgen and growth hormones.
- Analysis of the current and future competition in the global sarcopenia therapeutics market. The key market player covered is GTx.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the sarcopenia therapeutics market.
- Analysis of key recent licensing and partnership agreements in sarcopenia theapeutics market.
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Sarcopenia therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Sarcopenia therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What's the next big thing in the global Sarcopenia therapeutics market landscape? – Identify, understand and capitalize.
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 5
1.2 List of Figures 6
2 Sarcopenia Therapeutics Market : Executive Summary 8
2.1 The Sarcopenia Therapeutics Market Is Forecasted to Show Consistent Growth till 2018 8
2.2 Lack of First-in-Class products in the Pipeline, Result in a Weak Pipeline for Sarcopenia Therapeutics Market 9
2.3 Current Sarcopenia Therapeutics Market is Weak due to the Availability of Limited Treatment Options 9
2.4 Current Treatment Options Leaves a High Unmet Need 9
3 Sarcopenia Therapeutics: Introduction 11
3.1 Overview 11
3.2 Etiology and Pathophysiology 12
Loss of Neuro-muscular Function: 13
Hormonal Changes 13
Muscle Protein Breakdown: 13
Physical Activity 13
Mitochondrial Dysfunction 13
Apoptosis 13
3.3 Epidemiology 15
3.3.1 Global: 15
3.3.2 The US: 15
3.3.3 The UK: 16
3.3.4 Spain: 16
3.3.5 France: 16
3.3.6 Italy: 16
3.3.7 Japan: 16
3.3.8 Pharmaco-economic Burden 17
3.3.9 Quality of Life (QoL) 17
3.4 Symptoms 18
3.5 Diagnosis 18
3.5.1 Patient's History 19
3.5.2 Muscle Mass 19
3.5.3 Muscle Strength 20
3.5.4 Physical Performance 20
3.6 Treatment and Management Pattern 21
3.7 Referral Pathway 25
3.8 GlobalData Pipeline Report Guidance 26
4 Sarcopenia Therapeutics: Market Characterization 28
4.1 Overview 28
4.2 Sarcopenia Therapeutics Market Size 28
4.3 Sarcopenia Therapeutics Market Size (2005-2010) – Global 28
4.4 Sarcopenia Therapeutics Market Forecast (2010-2018) – Global 29
4.5 Sarcopenia Therapeutics Market Size (2005-2010) –The US 30
4.6 Sarcopenia Therapeutics Market Forecast (2010-2018) – The US 31
4.7 Sarcopenia Therapeutics Market Size (2005-2010) – Italy 32
4.8 Sarcopenia Therapeutics Market Forecast (2010-2018) – Italy 33
4.9 Sarcopenia Therapeutics Market Size (2005-2010) – The UK 34
4.10 Sarcopenia Therapeutics Market Forecast (2010-2018) – The UK 35
4.11 Sarcopenia Therapeutics Market Size (2005-2010) – Japan 36
4.12 Sarcopenia Therapeutics Market Forecast (2010-2018) – Japan 37
4.13 Drivers and Barriers 38
4.13.1 Drivers of the Sarcopenia Market 39
4.13.2 Barriers for the Sarcopenia Market 39
4.14 Opportunity and Unmet needs 40
4.15 Key Takeaway 41
5 Sarcopenia Therapeutics Market – Competitive Assessment 42
5.1 Overview 42
5.2 Strategic Competitor Assessment 42
5.3 Product Profile for the Major Marketed Products in the Sarcopenia Therapeutics market 43
5.3.1 Testosterone 43
5.3.2 Estrogen: 44
5.4 Key Takeaway 45
6 Sarcopenia Therapeutics: Pipeline Assessment 46
6.1 Overview 46
6.2 Strategic Pipeline Assessment 46
6.3 Pipeline by Phases of Development 46
6.3.1 Sarcopenia Therapeutics-Phase II Pipeline 47
6.3.2 Sarcopenia Therapeutics-Phase I Pipeline 47
6.3.3 Sarcopenia Therapeutics-Pre-Clinical Pipeline 47
6.4 Sarcopenia Therapeutics Market – Pipeline by Mechanism of Action 48
6.5 Technology Trends Analytic Framework 48
6.6 Promising Drugs under Development 50
6.7 Molecule Profile for Drugs under Clinical Development 50
6.7.1 MK-0773 50
6.8 Key Takeaway 51
7 Sarcopenia Therapeutics:Clinical Trials Mapping 52
7.1 Clinical Trials by Region/Country the US, EU5 and Japan) 52
7.2 Clinical Trials by Phase 53
7.3 Clinical Trials by Trial Status 53
7.4 Prominent Sponsors 54
7.5 Top Companies Participating in Therapeutics Clinical Trials 56
8 Sarcopenia Therapeutics:Strategic Assessment 58
8.1 Key Events Impacting the Future Market 58
8.2 Future Market Competition Scenario 58
9 Sarcopenia:Future Players 60
9.1 Introduction 60
9.2 Company Profiles 60
9.2.1 GTx, Inc. 60
9.3 Other Companies in Sarcopenia Therapeutics Market 62
10 Sarcopenia Therapeutics: Liscensing and Partnership Deals 63
11 Appendix 64
11.1 Market Definitions 64
11.2 Abbreviations 64
11.3 Methodology 66
11.3.1 Coverage 66
11.3.2 Secondary Research 66
11.3.3 Forecasting 66
11.3.4 Primary Research 68
11.3.5 Expert Panel Validation 69
11.4 Contact Us 69
11.5 Disclaimer 69
11.6 Bibliography 69
List of Tables
Table 1: Types of Sarcopenia 12
Table 2: Prevalence Patterns of Sarcopenia based on Different Studies (Skeletal Muscle Mass over 2 SD below Young Controls) 17
Table 3: Sarcopenia Therapeutics – Diagnostic Techniques 19
Table 4: Summary of Treatment Options for the treatment of sarcopenia 22
Table 5: Sarcopenia Therapeutics Market, Global, Revenue ($m), 2005-2010 29
Table 6: Sarcopenia Therapeutics Market, Global, Forecast ($m), 2010-2018 30
Table 7: Sarcopenia Therapeutics Market, the US, Revenue ($m), 2005-2010 31
Table 8: Sarcopenia Therapeutics Market, the US, Forecast ($m), 2010-2018 32
Table 9: Sarcopenia Therapeutics Market, Italy, Revenue ($m), 2005-2010 33
Table 10: Sarcopenia Therapeutics Market, Italy, Forecast ($m), 2010-2018 34
Table 11: Sarcopenia Therapeutics Market, The UK, Revenue ($m), 2005-2010 35
Table 12: Sarcopenia Therapeutics Market, The UK, Forecast ($m), 2010-2018 36
Table 13: Sarcopenia Therapeutics Market, Japan, Revenue ($m), 2005-2010 37
Table 14: Sarcopenia Therapeutics Market, Japan, Forecast ($m), 2010-2018 38
Table 15: Sarcopenia Therapeutics – Phase II Pipeline, 2011 47
Table 16: Sarcopenia Therapeutics – Phase I Pipeline, 2011 47
Table 17: Sarcopenia Therapeutics – Pre Clinical Pipeline, 2011 47
Table 18: Sarcopenia Therapeutics –Clinical Trials by Region, 2011 52
Table 19: Sarcopenia Therapeutics –Clinical Trials by Phase of Development, 2011 53
Table 20: Sarcopenia Therapeutics, Global, Clinical Trials by Trial Status, 2011 54
Table 21: Sarcopenia Therapeutics, Global, Clinical Trials by Prominent Sponsors, 2011 56
Table 22: Sarcopenia Therapeutics, Global, Clinical Trials by Top Companies, 2011 57
Table 23: GTx, Inc. - Pipeline, 2010 61
Table 24: Sarcopenia Therapeutics Market – Future Players, 2011 62
List of Figures
Figure 9: Sarcopenia Therapeutics Market, Global, Revenue ($m), 2005-2010 8
Figure 2: Opportunity and Unmet Need in the Sarcopenia Therapeutics Market, 2010 10
Figure 3: Are Related Changes in the Muscle Fibre 11
Figure 4: Sarcopenia Therapeutics – Pathophysiology 14
Figure 5: Disease Progression in Sarcopenia 15
Figure 6: Sarcopenia Therapeutics – Treatment And Management 21
Figure 7: Referral Pathway for Sarcopenia Disease 25
Figure 8: Algorithm for Sarcopenia 26
Figure 9: Sarcopenia Therapeutics Market, Global, Revenue ($m), 2005-2010 29
Figure 10: Sarcopenia Therapeutics Market, Global, Forecast ($m), 2010-2018 30
Figure 11: Sarcopenia Therapeutics Market, the US, Revenue ($m), 2005-2010 31
Figure 12: Sarcopenia Therapeutics Market, the US, Forecast ($m), 2010-2018 32
Figure 13: Sarcopenia Therapeutics Market, Italy, Revenue ($m), 2005-2010 33
Figure 14: Sarcopenia Therapeutics Market, Italy, Forecast ($m), 2010-2018 34
Figure 15: Sarcopenia Therapeutics Market, The UK, Revenue ($m), 2005-2010 35
Figure 16: Sarcopenia Therapeutics Market, The UK, Forecast ($m), 2010-2018 36
Figure 17: Sarcopenia Therapeutics Market, Japan, Revenue ($m), 2005-2010 37
Figure 18: Sarcopenia Therapeutics Market, Japan, Forecast ($m), 2010-2018 38
Figure 19: Opportunity and Unmet Need in the Sarcopenia Therapeutics Market, 2011 40
Figure 20: Sarcopenia Therapeutics, Strategic Competitor Assessment, 2011 42
Figure 21: Sarcopenia Therapeutics, Structure of Testosterone 2011 44
Figure 22: Sarcopenia Therapeutics, Structure of Estrogen 2011 44
Figure 23: Sarcopenia Therapeutics Pipeline by Phase of Development, 2011 46
Figure 24: Sarcopenia Therapeutics Market – Pipeline by Mechanism of Action, 2011 48
Figure 25: Technology Trends Analytic Framework of the Sarcopenia Therapeutics Pipeline, 2011 49
Figure 26: Technology Trends Analytic Framework of the Sarcopenia Therapeutics Pipeline- Description, 2011 50
Figure 27: Sarcopenia Therapeutics –Clinical Trials by Region, 2011 51
Figure 28: Sarcopenia Therapeutics –Clinical Trials by Region, 2011 52
Figure 29: Sarcopenia Therapeutics, Global, Clinical Trials by Phase of Development, 2011 53
Figure 30: Sarcopenia Therapeutics, Global, Clinical Trials by Trial Status, 2011 54
Figure 31: Sarcopenia Therapeutics, Global, Clinical Trials by Overall Sponsors, 2011 55
Figure 32: Sarcopenia Therapeutics, Global, Clinical Trials by Prominent Sponsors, 2011 55
Figure 33: Sarcopenia Therapeutics, Global, Clinical Trials by Top Companies, 2011 56
Figure 34: Key Events Competition in the Sarcopenia, 2011 58
Figure 35: Implications for Future Market Competition in the Sarcopenia, 2011 59
Figure 36: Sarcopenia Therapeutics Market – Clinical Pipeline by Company, 2011 60GTx, Inc.
To order this report:
Drug and Medication Industry: Sarcopenia Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Drug and Medication Business News
Check our Industry Analysis and Insights
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article